Highest-materiality recent filing
Pulmatrix Q1 net loss $1.2M, cash $3.3M; merger with Eos SENOLYTIX set for Q3 2026
Net loss $1.172M ($0.32/share) vs $1.808M ($0.50/share) in Q1 2025; no revenue reported.
Pulmatrix closes $1M Series B preferred placement as part of planned merger with Eos
Gross proceeds of approximately $1 million from Series B Preferred Stock issued to Eos affiliate.
Pulmatrix to merge with Eos SENOLYTIX; Eos stockholders to own ~94% of combined company
Pre-Merger Eos stockholders to own ~94% of combined company; Pulmatrix stockholders ~6% on fully-diluted basis.
Pulmatrix merger with Cullgen terminated; seeks alternative merger opportunities
Cullgen terminated the Merger Agreement on Feb 28, 2026 citing failure to obtain China Securities Regulatory Commission approval.
Pulmatrix: $0 revenue in 2025, net loss $5.2M, plans to license iSPERSE
Revenue $0 in 2025 vs $7.8M in 2024; net loss $5.2M ($1.41/share) vs $9.6M.
Pulmatrix and Cullgen waive no-solicitation clause, explore alternatives due to CSRC delay
Parties mutually waived the 'No Solicitation' clause (Section 5.4) of the Nov 2024 Merger Agreement.
Pulmatrix Q3 net loss $877K; pursues asset divestment for Cullgen merger
Net loss $877K ($0.24 per share); revenues $0 vs $0.4M YoY; cash $4.8M sufficient into Q4 2026.
Revenue fell to $0 from $1.6M in Q2 2024 due to PUR1900 wind-down; net loss $1.549M ($0.42 per share).
Pulmatrix stockholders approve merger proposals; CSRC clearance still outstanding
All seven proposals approved by stockholders at June 16 special meeting, including issuance of shares for Cullgen merger.
Pulmatrix reports Q1 loss; plans asset divestment, Cullgen merger close targeted for June
Q1 2025 revenue $0 vs $5.9M YoY; net loss $1.8M (-$0.50 EPS) vs net income $0.825M in Q1 2024.
Pulmatrix and Cullgen amend merger agreement to one-step merger; Second Merger Sub removed
Amendment No. 1 dated April 7, 2025 changes transaction from two-step to one-step merger, eliminating Second Merger Sub.
Pulmatrix auditor change: Marcum resigns, CBIZ engaged effective April 4, 2025
Marcum LLP resigned as independent auditor on April 4, 2025; no adverse opinions or disagreements in prior reports.
Pulmatrix reports 2024 net loss of $9.6M; proposes merger with Cullgen and asset divestment
Net loss for 2024 of $9.6M ($2.62 per share) vs $14.1M ($3.87 per share) in 2023.
Pulmatrix amends bylaws to revise voting standards language
Board approved Amendment No. 2 on Feb 11, 2025, effective immediately.
Pulmatrix stockholders elect two Class I directors, ratify auditor at 2024 annual meeting
Elected Todd Bazemore and Christopher Cabell as Class I directors with votes for 285,646 and 334,230, respectively.
Pulmatrix to merge with Cullgen in reverse merger; Cullgen holders to own 96.4%
Pulmatrix to merge with Cullgen; exchange ratio implies Cullgen valuation of $280M, Pulmatrix $10.5M.
Pulmatrix Q3 2024 revenue down 79% YoY to $0.4M; cash runway into Q4 2026
Net loss $2.6M ($0.71 per share) vs $3.8M ($1.03) in Q3 2023.
Pulmatrix sets 2024 annual meeting for Dec 18; Oct 31 record date
2024 Annual Meeting scheduled for Wednesday, December 18, 2024.
Pulmatrix Q2 2024 net loss widens to $5.8M; cash runway extended to Q4 2026
Net loss widened to $5.8M ($1.59/sh) from $3.8M ($1.04) a year ago; revenue fell to $1.6M from $1.8M.
CEO Teofilo Raad departs Pulmatrix; Peter Ludlum appointed Interim CEO
Teofilo Raad separated as CEO and Board member effective July 19, 2024; severance includes $567,294 salary, $156,310 prorated bonus, $283,647 separation bonus.
Pulmatrix cross-licenses iSPERSE with MannKind; transfers Bedford R&D facility to extend cash runway
Pulmatrix grants MannKind exclusive iSPERSE licenses for clofazimine, NTM lung disease, insulin; non-exclusive for endocrine, ILD.
All PUR3100 doses showed mean Cmax above 1000 pg/mL efficacy threshold; Tmax 5 min vs 5.5 min for IV DHE.
Pulmatrix Q1 rev $5.9M, net income $0.8M; PUR1900 study wind down, cash runway into Q1 2026
Revenue $5.9M (up $4.4M YoY) due to Cipla contract modification catch-up.
the Board approved the appointment of Peter Ludlum as the Interim Chief Executive Officer (the “Interim CEO”), effective as of July 20, 2024
Effective as of the Separation Date, Mr. Raad’s employment with the Company shall cease and Mr. Raad shall relinquish all positions, offices, and authority with the Company and any affiliates, including as a member of the Board
Max materiality 1.00 · Median 0.70 · Most common event earnings